WATERTOWN, Mass.--(BUSINESS WIRE)-- Arranta Bio announced today that it has reached a settlement of its litigation with Thermo Fisher Scientific. The settlement follows an April 4, 2023 Delaware Court of Chancery ruling that Arranta Bio was not subject to any non-competition obligations in its 2020 supply agreement with Thermo Fisher to develop plasmids. The specific terms of the settlement were not disclosed. The company offered the following statement:

“Arranta Bio is pleased with the settlement and has known from the outset that it was on firm legal ground. We will continue with our delivery of plasmid products for our customers and, ultimately, the patients that we serve. With the litigation resolved, Arranta Bio is well positioned and excited about our growth prospects and the future.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20230605005298/en/